Figure 2From: A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomidePlatelet transfusions administered. A) Total platelet units received and B) total number of platelet transfusions administered.Back to article page